These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 3840089)

  • 1. Pharmacokinetics of sustained-release verapamil after a single administration and at steady state.
    Mattila J; Mäntylä R; Taskinen J; Männistö P
    Eur J Drug Metab Pharmacokinet; 1985; 10(2):133-8. PubMed ID: 3840089
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of verapamil and norverapamil in patients with hypertension: a comparison of oral conventional and sustained release formulations.
    Jørgensen NP; Walstad RA
    Pharmacol Toxicol; 1988 Aug; 63(2):105-7. PubMed ID: 3186615
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sustained-release verapamil: multiple-dose pharmacokinetic comparison of 120-mg and 240-mg tablets and the effect of halving a 240-mg tablet.
    McEwen J; Durnin C; McMurdo ME; Moreland TA
    J Cardiovasc Pharmacol; 1989; 13 Suppl 4():S57-9. PubMed ID: 2475689
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multiple dose comparison of a whole 240 mg verapamil sustained-release tablet with two half tablets.
    Moreland TA; McMurdo ME; McEwen J
    Biopharm Drug Dispos; 1989; 10(3):311-9. PubMed ID: 2720134
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of conventional and slow-release verapamil.
    Follath F; Ha HR; Schütz E; Bühler F
    Br J Clin Pharmacol; 1986; 21 Suppl 2(Suppl 2):149S-153S. PubMed ID: 3756058
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Spline functions in convolutional modeling of verapamil bioavailability and bioequivalence. II: study in healthy volunteers.
    Popović J; Mitić R; Sabo A; Mikov M; Jakovljević V; Daković-Svajcer K
    Eur J Drug Metab Pharmacokinet; 2006; 31(2):87-96. PubMed ID: 16898076
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Faster clearance of sustained release verapamil in men versus women: continuing observations on sex-specific differences after oral administration of verapamil.
    Krecic-Shepard ME; Barnas CR; Slimko J; Schwartz JB
    Clin Pharmacol Ther; 2000 Sep; 68(3):286-92. PubMed ID: 11014410
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of food on the bioavailability of a sustained-release verapamil preparation.
    Conway EL; Phillips PA; Drummer OH; Louis WJ
    J Pharm Sci; 1990 Mar; 79(3):228-31. PubMed ID: 2338632
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of terbutaline given in slow-release tablets.
    Nyberg L; Kennedy BM
    Eur J Respir Dis Suppl; 1984; 134():119-39. PubMed ID: 6586473
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of bioavailability of experimental single-unit sustained release tablets of verapamil hydrochloride using the stable isotope technique.
    Marvola M; Kannikoski A; Taskinen J; Ottoila P
    J Pharm Pharmacol; 1985 Nov; 37(11):766-70. PubMed ID: 2867156
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasma levels and urinary excretion of verapamil, norverapamil, N-dealkylverapamil (D617), N-dealkylnorverapamil (D620) following oral administration of a slow-release preparation.
    Barbieri E; Padrini R; Piovan D; Toffoli M; Cargnelli G; Trevi G; Ferrari M
    Int J Clin Pharmacol Res; 1985; 5(2):99-107. PubMed ID: 4018947
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative efficacy, safety and pharmacokinetics of verapamil SR vs verapamil IR in hypertensive patients.
    Fuenmayor NT; Faggin BM; Cubeddu LX
    Drugs; 1992; 44 Suppl 1():1-11. PubMed ID: 1283570
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of verapamil and norverapamil from controlled release floating pellets in humans.
    Sawicki W
    Eur J Pharm Biopharm; 2002 Jan; 53(1):29-35. PubMed ID: 11777750
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Bioavailability of two verapamil formulations following repeated administration in steady-state conditions. An open, two-period, crossover study].
    Heintz B; Müller A; Lenhard G; Schütz M; Hutt HJ
    Arzneimittelforschung; 1996 Nov; 46(11):1060-3. PubMed ID: 9065315
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bioavailability of theophylline from a sustained-release aminophylline formulation (Euphyllin retard tablets)--plasma levels after single and multiple oral doses.
    Schuppan D; Molz KH; Staib AH; Rietbrock N
    Int J Clin Pharmacol Ther Toxicol; 1981 May; 19(5):223-7. PubMed ID: 7251238
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A steady-state evaluation of the bioavailability of chronotherapeutic oral drug absorption system verapamil PM after nighttime dosing versus immediate-acting verapamil dosed every eight hours.
    Prisant LM; Devane JG; Butler J
    Am J Ther; 2000 Nov; 7(6):345-51. PubMed ID: 11304641
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Absorption of theophylline from conventional and sustained-release tablets.
    Fagerström PO; Mellstrand T; Svedmyr N
    Int J Clin Pharmacol Ther Toxicol; 1981 Mar; 19(3):131-8. PubMed ID: 7228455
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics of verapamil and its metabolite norverapamil from a buccal drug formulation.
    Sawicki W; Janicki S
    Int J Pharm; 2002 May; 238(1-2):181-9. PubMed ID: 11996822
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of food on the pharmacokinetics and electrocardiographic effects of sustained release verapamil in normal subjects.
    Hoon TJ; McCollam PL; Beckman KJ; Hariman RJ; Bauman JL
    Am J Cardiol; 1992 Oct; 70(11):1072-6. PubMed ID: 1414906
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sustained-release and instant-release verapamil in treatment of angina pectoris.
    Jespersen CM; Klitgaard NA; Nielsen H; Hansen JF
    Eur J Clin Pharmacol; 1989; 36(6):625-7. PubMed ID: 2776821
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.